Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics

← Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics22 okt · 1 u 31 min

What New Research Reveals About Reversing Cognitive Decline

What New Research Reveals About Reversing Cognitive Decline22 okt1 u 31 min

What if cognitive decline isn't always a one-way street? For decades, the conventional approach to Alzheimer's disease and cognitive impairment has focused largely on slowing progression. But emerging research is challenging that assumption—and raising important questions about what may be possible when we address the multiple factors contributing to brain dysfunction.

In this episode of New Frontiers in Functional Medicine, Dr. Kara Fitzgerald welcomes Dr. Dale Bredesen and Dr. Kat Toups to discuss their recently completed randomized controlled trial investigating a personalized, systems-based approach to cognitive decline. The nine-month study enrolled 73 participants across six sites and reported significant improvements in several measures of cognitive function, including memory, processing speed, and overall neurocognitive performance.

The conversation goes beyond the headline results to examine the metabolic, inflammatory, hormonal, infectious, and environmental factors that may contribute to cognitive impairment. They also explore a surprising finding: cognitive improvements were not accompanied by equally dramatic changes in traditional Alzheimer's blood biomarkers, raising questions about how we measure meaningful recovery.

From ketogenic nutrition and exercise to sleep optimization, hormone health, targeted testing, and multidisciplinary coaching, Drs. Bredesen and Toups share the clinical thinking behind their precision medicine protocol, what the trial revealed, and what researchers still need to understand.

For clinicians working in functional medicine, brain health, and longevity—and anyone interested in the evolving science of Alzheimer's prevention and cognitive health—this episode offers a compelling look at the possibilities and remaining questions surrounding personalized interventions for cognitive decline.

In this episode of New Frontiers, learn about:

A New Randomized Trial for Cognitive Decline: What a nine-month, 73-participant study revealed about personalized precision medicine, including improvements in memory, processing speed, and overall cognitive function compared with standard care.Reversing Cognitive Decline vs. Slowing Progression: Why Drs. Bredesen and Toups believe a systems-based approach may offer opportunities beyond conventional symptom management—and what the results do and don't establish.The Alzheimer's Biomarker Paradox: Why substantial cognitive improvements occurred without equally significant changes in amyloi